Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Skye Bioscience Inc (OP: SKYE )

0.0174 +0.0004 (+2.35%)
Streaming Delayed Price Updated: 3:55 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,251,381
Open 0.0154
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0170
Today's Range 0.0150 - 0.0179
52wk Range 0.0105 - 0.0595
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma
Skye Bioscience, Inc. 
Via Benzinga
Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion
San Diego, California--(Newsfile Corp. - March 15, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
Via Newsfile

Performance

YTD
+4.19%
+4.19%
1 Month
-38.52%
-38.52%
3 Month
+7.41%
+7.41%
6 Month
-33.08%
-33.08%
1 Year
-54.09%
-54.09%

More News

Read More
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
Via Benzinga
Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Via Newsfile
Topics Derivatives
Exposures Derivatives
SOL Global Reduces Principal Amount Of Credit Facility From $50M To $4.52M, Announces Management Changes
Via Benzinga
Skye Receives Positive Safety Review Of Cannabinoid Based Drug For Treatment Of Glaucoma After Second Cohort Of Phase 1 Study
Via Benzinga
Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study
Via Newsfile
Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
Via Newsfile
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
Via Newsfile
Topics Cannabis
Exposures Cannabis
Skye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Via Newsfile
Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
Via Newsfile
Topics Derivatives
Exposures Derivatives
Skye Bioscience Achieves Positive Safety Review of SBI-100 Ophthalmic Emulsion After Phase 1 First Cohort
Via Newsfile
Skye One Step Closer To Phase 2 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
Via Benzinga
Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion
Via Newsfile
Exposures Product Safety
Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.
From Pharmaceutics International Inc.
Via Globe NewsWire
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
Via Benzinga
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
Via Newsfile
Exposures Product Safety
Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down
Via Benzinga
Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Via Newsfile
Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer
Via Newsfile
Topics Derivatives Intellectual Property
Exposures Derivatives Intellectual Property
Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference
Via Newsfile
Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
Via Newsfile
Topics Derivatives
Exposures Derivatives
Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
Via Benzinga
Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100
Via Newsfile
Skye Bioscience Closes Acquisition of Emerald Health Therapeutics
Via Newsfile
Topics Cannabis
Exposures Cannabis Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.